Immunotherapy Highly Active in Small Study of Advanced CTCL

(MedPage Today) — HOUSTON — Patients with advanced or refractory cutaneous T-cell lymphoma (CTCL) achieved near-100% disease control with single-agent immunotherapy or an immuno-oncology (IO) combination, a small randomized trial showed.
Eight…